Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts.

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit as a whole — to educate patients about the drug’s expanded uses.